Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUSTRAL Trial: Radiotherapy Followed By Durvalumab And Ceralasertib In Stage III NSCLC
NCT06680050Phase 2Recruiting
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Aug 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ceralasertib in non-small cell lung cancer (NSCLC), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoints: Number of grade 3 or higher adverse events at 6 months and Progression-Free Survival at 12 months. Started Aug 2025; status: recruiting.
02
Drugs
ceralasertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06680050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680050.